Search Results - "Sadik Shaik, J"

First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1 by Hansen, A., Bauer, T.M., Moreno, V., Maio, M., Groenland, S., Martin-Liberal, J., Gan, H., Rischin, D., Millward, M., Olszanski, A.J., Cho, D.C., Paul, E., Ballas, M., Ellis, C., Zhou, H., Yadavilli, S., Sadik Shaik, J., Schmidt, E.V., Hoos, A., Angevin, E.

Get full text

Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study by Maio, M., Groenland, S.L., Bauer, T., Rischin, D., Gardeazabal, I., Moreno, V., Trigo Perez, J.M., Chisamore, M., Sadik Shaik, J., Rigat, F., Ellis, C., Chen, H., Gagnon, R., Scherer, S., Turner, D., Yadavilli, S., Ballas, M., Hoos, A., Angevin, E.

Get full text

1971P - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study by Maio, M., Groenland, S.L., Bauer, T., Rischin, D., Gardeazabal, I., Moreno, V., Trigo Perez, J.M., Chisamore, M., Sadik Shaik, J., Rigat, F., Ellis, C., Chen, H., Gagnon, R., Scherer, S., Turner, D., Yadavilli, S., Ballas, M., Hoos, A., Angevin, E.

“…GSK609 an agonist non-T cell depleting IgG4 monoclonal antibody (mAb) against inducible co-stimulatory receptor (ICOS) exhibits T cell mediated immune…”
Get full text

1971PPharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study by Maio, M, Groenland, S L, Bauer, T, Rischin, D, Gardeazabal, I, Moreno, V, Trigo Perez, J M, Chisamore, M, Sadik Shaik, J, Rigat, F, Ellis, C, Chen, H, Gagnon, R, Scherer, S, Turner, D, Yadavilli, S, Ballas, M, Hoos, A, Angevin, E

“…Abstract Background GSK609 an agonist non-T cell depleting IgG4 monoclonal antibody (mAb) against inducible co-stimulatory receptor (ICOS) exhibits T cell…”
Get full text

Distribution of long-acting injection in healthy adult participants by Weld, E, Shaik, J. Sadik, Edick, S, Fuchs, E, Riddler, S, Marzinke, M, D'Amico, R, Bakshi, K, Lou, Y, Hendrix, C.W, Han, K, Ford, S.L, Margolis, D, Spreen, W, Patel, P

“…Background: CAB LA dosed at 2-month intervals demonstrated viro-logic efficacy in maintaining HIV-1 suppression as part of a dual regimen with rilpivirine LA…”
Get full text

Distribution of long-acting by Edick, S, Han, K, Spreen, W, D'Amico, R, Bakshi, K, Shaik, J. Sadik, Fuchs, E, Margolis, D, Riddler, S, Weld, E, Patel, P, Ford, S.L, Hendrix, C.W, Lou, Y, Marzinke, M

“…Background: CAB LA dosed at 2-month intervals demonstrated viro-logic efficacy in maintaining HIV-1 suppression as part of a dual regimen with rilpivirine LA…”
Get full text

1138PDFirst in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1 by Hansen, A, Bauer, T M, Moreno, V, Maio, M, Groenland, S, Martin-Liberal, J, Gan, H, Rischin, D, Millward, M, Olszanski, A J, Cho, D C, Paul, E, Ballas, M, Ellis, C, Zhou, H, Yadavilli, S, Sadik Shaik, J, Schmidt, E V, Hoos, A, Angevin, E

Get full text